Sepsis is a serious condition where the body responds improperly to an infection. Every 2.8 seconds, someone dies of sepsis globally, yet no direct therapies exist beyond supportive care. Many clinical trials have investigated the role of Tumor Necrosis Factor (TNF) as a potential therapeutic target, but anti-TNF therapy has not proven to be a breakthrough in the sepsis field. Therefore, understanding how TNF triggers this devastating condition could be of help for millions of people worldwide.
Ghent, February 26, 2025 — 4Tissue, a pioneer in biotechnology that is revolutionizing regenerative medicine, has successfully completed an additional €1.5M funding round, consisting of €1M in equity investments and additional grants. This funding will support the further development of the company’s groundbreaking bioresorbable hydrogel technology, which has the potential to significantly improve breast reconstruction and other tissue regeneration applications. This represents an important step forward in the evolution of regenerative medicine, with a particular focus on women’s health.
Microfluidics is a technology that allows researchers to precisely manipulate and control tiny amounts of fluids within networks of channels typically smaller than a human hair. The approach is now achieving the extreme miniaturization necessary to truly enter the ‘lab-on-a-chip’ era, with profound implications for biological research and human health.
In line with its stellar name, AstriVax Therapeutics is a rising star in Belgian biotech. The company launched in 2022 with €30 million – the largest seed round ever raised by a KU Leuven spin-out – and rapidly became a clinical-stage company, using its plug-and-play platform to fast-track development of vaccines and immunotherapies.
Ghent, Belgium, 15 January 2025 – ONTOFORCE, a leader in semantic technology for life sciences, headquartered in Ghent, Belgium, and Rancho Biosciences, the leading data science services company headquartered in San Diego, California, have announced a joint collaboration. This partnership aims to transform high quality data-driven research and drug development, providing scientists with unparalleled insights that drive discovery and innovation in the life sciences.
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions.
Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network.
Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncology.
As 2025 comes peeking around the corner, we invite you to look back with us at some of the most exciting science topics we covered this year. From advances in women’s health, organoids, and organ-on-a-chip models to the challenges of data science and innovations in animal science and sustainable biotech; let us walk you through the Benelux life sciences landscape of 2024 as we reflect on the vast amount of knowledge and know-how characteristic to this region.
Leuven, Belgium – December 4th, 2024 – miDiagnostics is pleased to announce the completion of a €30 million Series D funding round, led by Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science. This investment will accelerate the development of a groundbreaking sterility test for batch release and related quality control tests for the BioPharma Industry, utilizing miDiagnostics’ proprietary qPCR technology.
Ghent, Belgium, 4 December 2024 – European health technology (HealthTech) is at a critical crossroad. Despite groundbreaking research, a thriving startup scene and ambitious talent, the sector struggles to translate innovation into actionable impact. Challenges such as regulatory restrictions, fragmented markets, and funding gaps are slowing progress, while the clock is ticking and other regions of the world are surging ahead.
Sepsis is a serious condition where the body responds improperly to an infection. Every 2.8 seconds, someone dies of sepsis globally, yet no direct therapies exist beyond supportive care. Many clinical trials have investigated the role of Tumor Necrosis Factor (TNF) as a potential therapeutic target, but anti-TNF therapy has not proven to be a breakthrough in the sepsis field. Therefore, understanding how TNF triggers this devastating condition could be of help for millions of people worldwide.
Ghent, February 26, 2025 — 4Tissue, a pioneer in biotechnology that is revolutionizing regenerative medicine, has successfully completed an additional €1.5M funding round, consisting of €1M in equity investments and additional grants. This funding will support the further development of the company’s groundbreaking bioresorbable hydrogel technology, which has the potential to significantly improve breast reconstruction and other tissue regeneration applications. This represents an important step forward in the evolution of regenerative medicine, with a particular focus on women’s health.
Microfluidics is a technology that allows researchers to precisely manipulate and control tiny amounts of fluids within networks of channels typically smaller than a human hair. The approach is now achieving the extreme miniaturization necessary to truly enter the ‘lab-on-a-chip’ era, with profound implications for biological research and human health.
In line with its stellar name, AstriVax Therapeutics is a rising star in Belgian biotech. The company launched in 2022 with €30 million – the largest seed round ever raised by a KU Leuven spin-out – and rapidly became a clinical-stage company, using its plug-and-play platform to fast-track development of vaccines and immunotherapies.
Ghent, Belgium, 15 January 2025 – ONTOFORCE, a leader in semantic technology for life sciences, headquartered in Ghent, Belgium, and Rancho Biosciences, the leading data science services company headquartered in San Diego, California, have announced a joint collaboration. This partnership aims to transform high quality data-driven research and drug development, providing scientists with unparalleled insights that drive discovery and innovation in the life sciences.
Galapagos intends to create a new company with approximately €2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions.
Galapagos will gain full global development and commercialization rights to its pipeline, focusing on accelerating cell therapies and building a global, decentralized manufacturing network.
Galapagos to implement a strategic reorganization to position the Company for long-term growth and cell therapy leadership in oncology.
As 2025 comes peeking around the corner, we invite you to look back with us at some of the most exciting science topics we covered this year. From advances in women’s health, organoids, and organ-on-a-chip models to the challenges of data science and innovations in animal science and sustainable biotech; let us walk you through the Benelux life sciences landscape of 2024 as we reflect on the vast amount of knowledge and know-how characteristic to this region.
Leuven, Belgium – December 4th, 2024 – miDiagnostics is pleased to announce the completion of a €30 million Series D funding round, led by Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science. This investment will accelerate the development of a groundbreaking sterility test for batch release and related quality control tests for the BioPharma Industry, utilizing miDiagnostics’ proprietary qPCR technology.
Ghent, Belgium, 4 December 2024 – European health technology (HealthTech) is at a critical crossroad. Despite groundbreaking research, a thriving startup scene and ambitious talent, the sector struggles to translate innovation into actionable impact. Challenges such as regulatory restrictions, fragmented markets, and funding gaps are slowing progress, while the clock is ticking and other regions of the world are surging ahead.